Clinical Trial: CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07451236) titled 'CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA' on Feb. 22.

Brief Summary: This is an early-stage, open-label clinical study of CD19-BCMA dual nanobody based CAR-T Cell desensitization therapy for patients positive for Donor-Specific Antibodies. Enrolled subjects will participate in an early clinical study using the traditional "3+3" dose escalation design to determine the Maximum Tolerated Dose (MTD) of CAR-T cell infusion (i.e., three escalating dose levels: 0.5x10^6 CAR+ T cells/kg, 1x10^6 CAR+ T cells/kg, 2x10^6 CAR+ T cells/kg). The investigators and the sponsor will jointly form a Safety Review Committee (SRC)...